낭포성 섬유증 시장 : 치료법별, 투여 경로별, 최종 사용자별, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Cystic Fibrosis Market is projected to grow by USD 13.61 billion at a CAGR of 9.79% by 2032.

Cystic Fibrosis Market Introduction

Cystic fibrosis is a life-limiting, autosomal recessive disease caused by pathogenic variants in the CFTR gene, leading to impaired chloride and bicarbonate transport, thick mucus, recurrent respiratory infections, pancreatic insufficiency, and multisystem complications. The cystic fibrosis market is shaped by a high clinical burden, lifelong treatment needs, and a rapidly evolving standard of care centered on CFTR modulators, airway clearance, anti-infectives, mucolytics, nutritional support, and multidisciplinary disease management.

Verified registry and foundation data indicate that more than 105,000 people are living with diagnosed cystic fibrosis across 90-plus countries, with the highest documented prevalence in North America and Europe. Earlier diagnosis through newborn screening, longer survival, and broader access to precision therapies are expanding the treated population, while health systems continue to address gaps in equitable access, genotype coverage, infection control, and long-term outcomes.

Transformative Shifts in the Cystic Fibrosis Landscape

The cystic fibrosis landscape has shifted from symptom management toward genotype-directed disease modification. CFTR modulators, particularly highly effective triple-combination therapy for eligible patients, have changed expectations for lung function, pulmonary exacerbation reduction, nutritional status, and quality of life. This transition is reshaping demand across pharmaceuticals, diagnostics, specialty pharmacy, companion testing, and longitudinal monitoring.

At the same time, unmet needs remain substantial for people with rare or nonresponsive CFTR variants, advanced lung disease, chronic Pseudomonas aeruginosa or Burkholderia cepacia complex infection, liver disease, cystic fibrosis-related diabetes, infertility, and treatment-related access barriers. The next competitive phase is expected to emphasize mutation-agnostic strategies, mRNA and gene editing platforms, inhaled delivery systems, antimicrobial resistance management, and real-world evidence demonstrating durable clinical value.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler across cystic fibrosis research and care. AI-supported image analysis can quantify structural lung disease from CT and MRI, while machine learning models are being evaluated to anticipate pulmonary exacerbations using spirometry, symptoms, microbiology, wearable data, and electronic health records. These tools can help clinicians identify deterioration earlier and personalize follow-up intensity.

AI is also accelerating drug discovery by supporting CFTR variant interpretation, protein-structure modeling, candidate screening, clinical trial enrichment, and pharmacovigilance. The cumulative impact is strongest when AI is paired with validated registries, standardized endpoints, and privacy-preserving data governance. Industry leaders should view AI as a decision-support layer rather than a replacement for specialist-led cystic fibrosis care.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

North America remains the most mature cystic fibrosis market, led by the United States and Canada, where newborn screening, accredited care centers, registries, and access to advanced CFTR modulators support high treatment penetration. Europe is similarly advanced, with strong specialist networks, national registries, and reimbursement pathways, although country-level access timelines differ across the European Union and non-EU markets.

Asia-Pacific is expanding through improved diagnosis, rising specialty-care capacity, and increasing awareness in China, India, Japan, South Korea, and Australia, but underdiagnosis and genotype diversity remain important constraints. Latin America, the Middle East, and Africa show growing clinical recognition and newborn screening adoption in select countries, yet access to modulators, sweat testing, genetic testing, and infection-control infrastructure remains uneven. These regional differences make market access, affordability, local evidence generation, and clinician training essential for sustainable growth.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

Within ASEAN, cystic fibrosis is historically underdiagnosed because the disease is less common than in populations of European ancestry and diagnostic infrastructure varies widely; however, expanding genomic medicine, pediatric pulmonology capacity, and referral networks are improving case identification. GCC countries are investing in specialized healthcare infrastructure, genetic testing, premarital and carrier screening programs, and rare disease pathways, creating opportunities for earlier diagnosis and precision treatment access.

The European Union benefits from coordinated rare disease policy, cross-border research networks, newborn screening expansion, and established cystic fibrosis registries, while BRICS markets present a mixed profile: China, India, and Brazil offer large population bases and improving specialty access, whereas affordability and diagnostic coverage remain key barriers. G7 markets lead in innovation, reimbursement sophistication, clinical trial infrastructure, and real-world evidence generation. NATO member countries overlap heavily with North American and European advanced-care markets, supporting strong clinical trial capacity, standardized treatment protocols, and high adoption of specialist-led care models.

Key Country Insights Across Major Cystic Fibrosis Markets

The United States is the global commercial anchor for cystic fibrosis innovation, supported by a large diagnosed population, advanced care-center infrastructure, newborn screening, and broad use of CFTR modulators among eligible patients. Canada shows similar clinical sophistication with centralized assessment, provincial reimbursement processes, and strong specialist care. Mexico and Brazil are strengthening diagnosis, newborn screening, and specialist access, but affordability and regional disparities continue to influence treatment uptake.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain robust cystic fibrosis care models, registries, newborn screening programs, and reimbursement systems, while Russia faces more variable access across regions. China and India are increasingly important due to expanding genetic testing, pediatric respiratory care, and rising rare disease awareness, though underdiagnosis remains significant. Japan, Australia, and South Korea combine high-quality healthcare systems with growing precision medicine adoption, supporting opportunities in diagnostics, specialty therapeutics, adherence support, and long-term outcome monitoring.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize broad genotype coverage, durable real-world outcomes, and access strategies that reflect local payer expectations. Developers of CFTR modulators, anti-infectives, mucolytics, gene-based therapies, or digital monitoring tools should invest early in biomarker validation, registry partnerships, patient-reported outcomes, and evidence packages that demonstrate reduced exacerbations, hospitalization avoidance, improved lung function, and better long-term quality of life.

Commercial and medical teams should also strengthen collaborations with cystic fibrosis centers, patient organizations, diagnostic laboratories, and public health agencies. Practical priorities include expanding newborn screening, improving sweat chloride and genetic testing access, supporting antimicrobial stewardship, reducing treatment burden, improving adherence support, and designing equitable access models for low- and middle-income markets.

Research Methodology

Research methodology is built from verified secondary research, including peer-reviewed cystic fibrosis literature, public health guidance, regulatory information, clinical trial databases, newborn screening references, patient registry insights, and publicly available information from recognized cystic fibrosis foundations and specialist organizations. Market interpretation emphasizes evidence that is clinically validated, reproducible, and relevant to industry decision-making.

The methodology combines disease epidemiology review, therapy landscape assessment, regional access evaluation, and qualitative analysis of innovation trends. Insights are triangulated across clinical standards, regulatory approvals, reimbursement patterns, registry findings, and real-world care infrastructure to provide an objective view of the cystic fibrosis market without relying on unsupported assumptions, market estimation, or forecasting.

Conclusion

The cystic fibrosis market is entering a new phase defined by precision medicine, earlier diagnosis, long-term disease modification, and rising expectations for equitable access. CFTR modulators have transformed outcomes for many eligible patients, but significant unmet needs persist for rare variants, advanced complications, chronic infection, and regions with limited diagnostic or reimbursement capacity.

Future leadership will depend on therapies and services that expand eligibility, reduce treatment burden, and prove durable value in real-world settings. Organizations that combine scientific innovation with strong access planning, registry-based evidence, and patient-centered care models will be best positioned in the global cystic fibrosis ecosystem.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cystic Fibrosis Market, by Treatment Type

• 7.1. CFTR Modulator Therapies
  • 7.1.1. Potentiators
  • 7.1.2. Correctors
  • 7.1.3. Amplifiers
  • 7.1.4. Combination Therapies
• 7.2. Symptomatic / Supportive Therapies
  • 7.2.1. Mucolytics
  • 7.2.2. Bronchodilators
  • 7.2.3. Antibiotics
  • 7.2.4. Anti-Inflammatory Drugs

8. Cystic Fibrosis Market, by Route Of Administration

• 8.1. Inhalation
• 8.2. Intravenous
• 8.3. Oral

9. Cystic Fibrosis Market, by End User

• 9.1. Home Healthcare
• 9.2. Hospitals
• 9.3. Specialty Clinics

10. Cystic Fibrosis Market, by Distribution Channel

• 10.1. Offline Pharmacy
  • 10.1.1. Hospital Pharmacy
  • 10.1.2. Retail Pharmacy
• 10.2. Online Pharmacy

11. Cystic Fibrosis Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Cystic Fibrosis Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Cystic Fibrosis Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abbott Laboratories
• 15.2. AbbVie Inc.
• 15.3. Alaxia SAS
• 15.4. Anthera Pharmaceuticals, Inc.
• 15.5. Arcturus Therapeutics Holdings Inc.
• 15.6. AstraZeneca PLC
• 15.7. Beyond Air, Inc.
• 15.8. Boehringer Ingelheim International GmbH
• 15.9. Chiesi Farmaceutici S.p.A.
• 15.10. Corbus Pharmaceuticals Holdings, Inc.
• 15.11. CRISPR Therapeutics AG
• 15.12. Editas Medicine, Inc.
• 15.13. Eloxx Pharmaceuticals, Inc.
• 15.14. F. Hoffmann-La Roche Ltd
• 15.15. Galapagos NV
• 15.16. GeneTx Biotherapeutics LLC
• 15.17. Gilead Sciences, Inc.
• 15.18. Insmed Incorporated
• 15.19. Johnson & Johnson Services, Inc.
• 15.20. Merck & Co., Inc.
• 15.21. Neovii Biotech GmbH
• 15.22. Novartis AG
• 15.23. Novo Nordisk A/S
• 15.24. Pharmaxis Ltd.
• 15.25. Proteostasis Therapeutics, Inc.
• 15.26. PTC Therapeutics, Inc.
• 15.27. Teva Pharmaceutical Industries Ltd.
• 15.28. Vertex Pharmaceuticals Incorporated
• 15.29. Viatris Inc.
• 15.30. Zambon S.p.A.